Overview

(VELA) Study of BLU-222 in Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Blueprint Medicines Corporation

Treatments:

Carboplatin
Fulvestrant